Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

13.5%

5 terminated/withdrawn out of 37 trials

Success Rate

86.5%

-0.0% vs industry average

Late-Stage Pipeline

27%

10 trials in Phase 3/4

Results Transparency

56%

18 of 32 completed trials have results

Key Signals

18 with results

Enrollment Performance

Analytics

Phase 2

19(51.4%)

Phase 3

9(24.3%)

Phase 1

8(21.6%)

Phase 4

1(2.7%)

37Total

Phase 2(19)

Phase 3(9)

Phase 1(8)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (37)

Showing 20 of 37 trials

NCT06493578Phase 2Terminated

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

Role: lead

NCT04940767Phase 4Completed

A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris

Role: collaborator

NCT02094716Phase 2Completed

A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies

Role: collaborator

NCT03836001Phase 2Completed

A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa

Role: collaborator

NCT04927572Phase 1Completed

Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis

Role: lead

NCT01951274Phase 2Completed

VPD-737 for Treatment of Chronic Pruritus

Role: lead

NCT02815267Phase 3Completed

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

Role: lead

NCT03271021Phase 3Completed

A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris

Role: lead

NCT02815280Phase 3Completed

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

Role: lead

NCT03276936Phase 3Completed

A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea

Role: lead

NCT02196324Phase 2Completed

A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)

Role: lead

NCT03540160Phase 3Terminated

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

Role: lead

NCT03546816Phase 3Completed

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Role: lead

NCT00835718Phase 2Terminated

A Study of MK0594 in Patients With Alcohol Dependence (0594-020)

Role: lead

NCT03282591Phase 2Completed

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough

Role: lead

NCT02975271Phase 2Terminated

Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury

Role: lead

NCT03677401Phase 3Completed

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Role: lead

NCT03841331Phase 2Completed

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin

Role: lead

NCT02975206Phase 2Completed

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

Role: lead

NCT03343639Phase 2Completed

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis

Role: lead